Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
- 7 December 2007
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 80 (2), 133-142
- https://doi.org/10.1111/j.1600-0609.2007.00995.x
Abstract
Objectives: Mantle cell lymphoma (MCL) is an incurable B cell lymphoma, and novel treatment strategies are urgently needed. We evaluated the effects of combined treatment with the proteasome inhibitor bortezomib and the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) on MCL. Bortezomib acts by targeting the proteasome, and – among other mechanisms – results in a reduced nuclear factor-kappa B (NF-κB) activity. HDACi promote histone acetylation, and also interfere with NF-κB signaling. Methods: Human MCL cell lines (JeKo-1, Granta-519 and Hbl-2) were exposed to bortezomib and/or SAHA. Cell viability and apoptosis were quantified by the MTT and annexin-V assay, respectively. Reactive oxygen species (ROS) were analyzed using the fluorophore H2DCFDA. In addition, activated caspases, proteasome- and NF-κB activity were quantified. Results: Combined incubation with bortezomib and SAHA resulted in synergistic cytotoxic effects, as indicated by combination index values N-acetyl-l-cysteine blocked the ROS generation and reduced the apoptosis significantly. In addition, coexposure of bortezomib and SAHA led to increased caspase-3, -8 and -9 activity, marked reduction of proteasome activity and decrease of NF-κB activity. Conclusions: This is the first report giving evidence that SAHA and bortezomib synergistically induce apoptosis in MCL cells. These data build the framework for clinical trials using combined proteasome and histone deacetylase inhibition in the treatment of MCL.Keywords
This publication has 51 references indexed in Scilit:
- NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cellsBlood, 2007
- Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaBlood, 2006
- Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cellsBiochemical and Biophysical Research Communications, 2006
- Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-κB activation by the HDAC inhibitor apicidinBiochemical and Biophysical Research Communications, 2006
- Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesisApoptosis, 2005
- Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionBiochemical and Biophysical Research Communications, 2005
- Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA BindingMolecular Cancer Research, 2005
- Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomesHuman Molecular Genetics, 2004
- Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clockExperimental Cell Research, 2004
- Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionZeitschrift für Krebsforschung und Klinische Onkologie, 2003